These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32553634)

  • 21. Tofacitinib treatment in a severe pediatric alopecia areata: A case report and a literature review.
    Ma Y; Wang W; Shi D
    Skin Res Technol; 2024 Jan; 30(1):e13553. PubMed ID: 38186061
    [No Abstract]   [Full Text] [Related]  

  • 22. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tofacitinib for severe alopecia areata: experience from a university tertiary hospital.
    Amoedo P; Matos PR; Mota A; Pedrosa AF
    Eur J Dermatol; 2024 Feb; 34(1):100-102. PubMed ID: 38557471
    [No Abstract]   [Full Text] [Related]  

  • 24. Rapidly progressive alopecia areata totalis in a COVID-19 patient, unresponsive to tofacitinib.
    Berbert Ferreira S; Gavazzoni Dias MFR; Berbert Ferreira R; Neves Neto AC; Trüeb RM; Lupi O
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e411-e412. PubMed ID: 33587766
    [No Abstract]   [Full Text] [Related]  

  • 25. Ruxolitinib for the treatment of severe alopecia areata.
    Liu LY; King BA
    J Am Acad Dermatol; 2019 Feb; 80(2):566-568. PubMed ID: 30195572
    [No Abstract]   [Full Text] [Related]  

  • 26. [Alopecia areata with good response to tofacitinib].
    Maksimow A; Stintzing D; Wohlrab J
    Hautarzt; 2021 Jun; 72(6):525-527. PubMed ID: 33044559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
    Salman A; Sarac G; Ergun T
    Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of longstanding alopecia areata universalis of the eyebrows/facial hair with oral and topical tofacitinib.
    Gonzalez Matheus GA; Herat A
    Dermatol Online J; 2022 Aug; 28(4):. PubMed ID: 36259869
    [No Abstract]   [Full Text] [Related]  

  • 29. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
    Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
    Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
    [No Abstract]   [Full Text] [Related]  

  • 30. Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata.
    Gordon SC; Abudu M; Zancanaro P; Ko JM; Rosmarin D
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e156-e157. PubMed ID: 30520145
    [No Abstract]   [Full Text] [Related]  

  • 31. Topical tofacitinib for the treatment of alopecia areata affecting facial hair.
    Kerkemeyer KLS; Sinclair RD; Bhoyrul B
    Br J Dermatol; 2021 Sep; 185(3):677-679. PubMed ID: 33914907
    [No Abstract]   [Full Text] [Related]  

  • 32. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis.
    Guo L; Feng S; Sun B; Jiang X; Liu Y
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):192-201. PubMed ID: 31494993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tofacitinib as a treatment of alopecia areata in adolescents.
    Morales-Miranda AY; Bueno-Arias GM; Aguirre-Félix ÓG; Tovar-Franco R
    Bol Med Hosp Infant Mex; 2019; 76(4):182-187. PubMed ID: 31303654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A retrospective study of oral tofacitinib therapy for alopecia areata.
    Lima XTV; Bambery M; Alora MB
    An Bras Dermatol; 2023; 98(2):221-224. PubMed ID: 36682967
    [No Abstract]   [Full Text] [Related]  

  • 35. Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib.
    Chen YL; Liu LX; Huang Q; Li XY; Hong XP; Liu DZ
    Front Immunol; 2021; 12():654376. PubMed ID: 33936080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tofacitinib for Treatment of Alopecia Areata: Real-world Evidence and Factors Associated with Therapeutic Response.
    Sanchez-Diaz M; Diaz-Calvillo P; Rodriguez-Pozo JA; Tercedor-Sánchez J; Cantudo-Cuenca MR; Molina-Leyva A; Arias-Santiago S
    Acta Derm Venereol; 2022 Jun; 102():adv00736. PubMed ID: 35578820
    [No Abstract]   [Full Text] [Related]  

  • 37. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata.
    Liu LY; King BA
    J Am Acad Dermatol; 2019 Jun; 80(6):1778-1779. PubMed ID: 30502414
    [No Abstract]   [Full Text] [Related]  

  • 39. JAK Inhibitors for the Treatment of Pediatric Alopecia Areata.
    Hamilton CE; Craiglow BG
    J Investig Dermatol Symp Proc; 2020 Nov; 20(1):S31-S36. PubMed ID: 33099381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response of alopecia areata of the beard to oral tofacitinib.
    Kerkemeyer KLS; John JM; Sinclair R; Bhoyrul B
    J Am Acad Dermatol; 2020 May; 82(5):1228-1230. PubMed ID: 31678329
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.